I started at Genentech in 2009 after a PhD in organic chemistry at Stanford. At Genentech I primarily work on antibody-drug conjugates for the treatment of cancer and infectious disease.
Genentech is a fantastic place to do translational research. We work in a highly collaborative environment with unparalleled resources and an emphasis on innovation. This enables post docs and their mentors to engage in addressing some of the most difficult scientific problems.
My research interests are broadly around utilizing synthetic chemistry and chemical biology to explore and develop medicines for oncology and infectious disease. Much of my research focuses on bioconjugation with an emphasis on antibody-drug conjugates (ADCs). We utilize ADCs to interrogate the ability of an antibody to selectively deliver a variety of molecules to the interior of a target cell.